With zero observation under Form 483
Cadila Healthcare announced that the USFDA inspected its API manufacturing facility at Dabhasa from 15 January 2018 to 19 January 2018. At the end of the inspection, no observation (483) is issued.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content